This section of PsoriasisTx.com includes articles on topics related to psoriasis drug treatments and the latest updates on safety and efficacy data. These articles may provide links to sites outside PsoriasisTx.com; we are not responsible for the content contained therein. The opinions, claims, and comments on those sites should not be attributed to PsoriasisTx.com. These articles are presented for the purpose of providing resources for PsoriasisTx.com users interested in the latest information on psoriasis drugs.
The abstracts below have been collected from the medical literature and include articles on the use of adalimumab, alefacept, efalizumab, etanercept, and infliximab for psoriasis, as well as on other psoriasis treatments. These abstracts and the articles from which they have been drawn are among the most important publications related to psoriasis, new psoriasis drugs, and updated clinical data.
Adalimumab
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
Saurat JH, Stingl G, Dubertret L., et al.
Br J Dermatol. 2008;158:558-66
Date Published: March 2008
Keywords:
View Abstract
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
Revicki D, Willian MK, Saurat JH., et al.
Br J Dermatol. 2008;158:549-57
Date Published: March 2008
Keywords:
View Abstract
Adalimumab: a new alternative biologic agent for chronic plaque psoriasis.
Ormerod AD.
Br J Dermatol. 2008;158:435-6
Date Published: March 2008
Keywords:
View Abstract
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
Papoutsaki M, Costanzo A, Chimenti MS., et al.
Expert Opin Biol Ther. 2008;8:363-70
Date Published: March 2008
Keywords:
View Abstract
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Menter A, Tyring SK, Gordon K., et al.
J Am Acad Dermatol. 2008;58:106-15
Date Published: January 2008
Keywords:
View Abstract
Adalimumab vs. etanercept in psoriasis.
Downs AM.
Clin Exp Dermatol. 2007;32:593
Date Published: September 2007
Keywords:
View Abstract
Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics.
Papoutsaki M, Chimenti MS, Costanzo A., et al.
J Am Acad Dermatol. 2007
Date Published: June 2007
Keywords:
View Abstract
Safety and Efficacy of Adalimumab in Treatment of Patients with Psoriatic Arthritis Who Had Failed Disease Modifying Antirheumatic Drug Therapy.
Genovese MC, Mease PJ, Thomson GT., et al.
J Rheumatol.
Date Published: April 2007
Keywords:
View Abstract
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD, Mease PJ, Ritchlin CT., et al.
Arthritis Rheum. 2007;56:476-88
Date Published: February 2007
Keywords:
View Abstract
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Gordon KB, Langley RG, Leonardi C., et al.
J Am Acad Dermatol. 2006;55:598-606
Date Published: October 2006
Keywords:
View Abstract
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept.
Shen C, Assche GV, Colpaert S, et al.
Aliment Pharmacol Ther. 2005;21:251-258.
Date Published: February 2005
Keywords: adalimumab, apoptosis, cells, colitis, Crohn's disease, cytokines, DNA, etanercept, immunoglobulin G, immunosuppressive agents, inflammatory bowel disease, infliximab, interleukins, mechanism of action, metabolism, mitochondria, monoclonal antibodies, monocytes, pathology, pharmacology, receptors, tumor necrosis factor (TNF)
View Abstract
Agents In Development
Interleukin-12, interleukin-23, and psoriasis: current prospects.
Torti DC , Feldman SR.
J Am Acad Dermatol. 2007;57:1059-68
Date Published: December 2007
Keywords:
View Abstract
Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275.
Reddy M, Davis C, Wong J., et al.
Cell Immunol. 2007;247:1-11
Date Published: August 2007
Keywords:
View Abstract
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.
Gottlieb AB , Cooper KD, McCormick TS., et al.
Curr Med Res Opin. 2007;23:1081-92
Date Published: May 2007
Keywords:
View Abstract
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Krueger GG, Langley RG, Leonardi C., et al.
N Engl J Med. 2007;356:580-92
Date Published: February 2007
Keywords:
View Abstract
Alefacept
The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.
Cafardi JA, Cantrell W, Wang W., et al.
Skinmed. 2008;7:67-72
Date Published: March 2008
Keywords:
View Abstract
Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
Chamian F, Lin SL, Lee E., et al.
J Transl Med. 2007;5:27
Date Published: June 2007
Keywords:
View Abstract
Therapeutic effects of a 12-week course of alefacept on nail psoriasis.
Korver JE, Langewouters AM, Van De Kerkhof PC., et al.
J Eur Acad Dermatol Venereol. 2006;20:1252-5
Date Published: November 2006
Keywords:
View Abstract
An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
Gribetz CH, Blum R, Brady C, et al.
J Am Acad Dermatol. 2005;53:73-75.
Date Published: July 2005
Keywords: adverse effects, alefacept, dosage, efficacy, open-label, PASI, phase II, phase III, psoriasis, randomized controlled trials, safety
View Abstract
Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use.
Korman NJ, Moul DK.
Semin Cutan Med Surg. 2005;24:10-18.
Date Published: March 2005
Keywords: alefacept, combination therapy, dosage, infections, PASI, psoriasis, quality of life, remission, safety, systemic therapy, T cells, T lymphocytes, transitioning, ultraviolet
View Abstract
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Lebwohl M, Christophers E, Langley R, et al, for the Alefacept Study Group.
Arch Dermatol. 2003;139:719-727.
Date Published: June 2003
Keywords: administration, adverse effects, alefacept, clinical trials, dosage, dose-response, efficacy, intramuscular injections, PASI, pathology, phase III, psoriasis, randomized controlled trials, recombinant fusion proteins, T cells, T lymphocytes
View Abstract
Alefacept therapy produces remission for patients with chronic plaque psoriasis.
Krueger GG, Ellis CN.
Br J Dermatol. 2003;148:784-788.
Date Published: April 2003
Keywords: alefacept, biologic agents, dose-response, follow-up studies, immunosuppressive agents, pathogenesis, phase II, Physician's Global Assessment (PGA), psoriasis, randomized controlled trials, rebound, recombinant fusion proteins, remission, T cells, T lymphocytes
View Abstract
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
Krueger GG, Papp KA, Stough DB, et al, for the Alefacept Clinical Study Group.
J Am Acad Dermatol. 2002;47:821-833.
Date Published: December 2002
Keywords: alefacept, clinical trials, courses, dose-response, efficacy, follow-up studies, intravenous, PASI, phase III, psoriasis, randomized controlled trials, recombinant fusion proteins, tolerability
View Abstract
Efalizumab
Thrombotic thrombocytopenic purpura with the use of efalizumab for psoriasis.
Thachil J, Martlew V.
Br J Dermatol. 2008;158:1138-9
Date Published: May 2008
Keywords:
View Abstract
Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness
Guttman-Yassky E, Vugmeyster Y, Lowes MA., et al.
J Invest Dermatol. 2008;128:1182-91
Date Published: May 2008
Keywords:
View Abstract
Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab.
Colsman A, Carrascosa JM, Ferrandiz C., et al.
J Eur Acad Dermatol Venereol. 2008;[Epub ahead of print]
Date Published: April 2008
Keywords:
View Abstract
Severe exacerbation of chronic plaque psoriasis following initially effective therapy with efalizumab: clinical characterization and therapeutic management.
Ulmer A, Wölbing F, Metzler G., et al.
Br J Dermatol. 2008;158:867-9
Date Published: April 2008
Keywords:
View Abstract
The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
Clark L, Lebwohl M.
J Am Acad Dermatol. 2008;58:443-6
Date Published: March 2008
Keywords:
View Abstract
Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.
Tsai TF, Liu MT, Liao YH., et al.
J Eur Acad Dermatol Venereol. 2008;22:345-52
Date Published: March 2008
Keywords:
View Abstract
Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation.
Bukhari IA.
Saudi Med J. 2007;28:1745-7
Date Published: November 2007
Keywords:
View Abstract
Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and ciclosporin.
Tuxen AJ, Yong MK, Street AC., et al.
Br J Dermatol. 2007;157:1067-8
Date Published: November 2007
Keywords:
View Abstract
Efalizumab-associated thrombocytopenia.
Hostetler SG, Zirwas M, Bechtel MA.
J Am Acad Dermatol. 2007;57:707-10
Date Published: October 2007
Keywords:
View Abstract
Efalizumab.
Chacko M, Weinberg JM.
Dermatol Ther. 2007;20:265-9
Date Published: July 2007
Keywords:
View Abstract
Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment
Carrascosa JM, Soria X, Ferrándiz C .
J Eur Acad Dermatol Venereol. 2007;21:828-829
Date Published: July 2007
Keywords:
View Abstract
Combination of efalizumab and acitretin in chronic plaque psoriasis
Gisondi P, Girolomoni G.
J Eur Acad Dermatol Venereol. 2007
Date Published: June 2007
Keywords:
View Abstract
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Menter A, Hamilton TK, Toth DP., et al.
Int J Dermatol. 2007;46:637-48
Date Published: June 2007
Keywords:
View Abstract
Efalizumab for the treatment of psoriatic arthritis.
Papp KA, Caro I, Leung HM., et al.
J Cutan Med Surg. 2007;11:57-66
Date Published: March 2007
Keywords:
View Abstract
Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial.
Sterry W, Stingl G, Langley RG., et al.
J Dtsch Dermatol Ges. 2006;4:947-56
Date Published: November 2006
Keywords:
View Abstract
Clinical considerations of efalizumab therapy in patients with psoriasis.
Hamilton TK.
Semin Cutan Med Surg. 2005;24:19-27.
Date Published: March 2005
Keywords: adverse effects, arthralgia, biologic agents, clinical trials, efalizumab, efficacy, flare, inflammatory, long-term treatment, monoclonal antibodies, papular eruption, psoriasis, remission, safety
View Abstract
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
Leonardi CL, Papp KA, Gordon KB, et al, for the Efalizumab Study Group.
J Am Acad Dermatol. 2005;52(3 pt 1):425-433.
Date Published: March 2005
Keywords: efalizumab, efficacy, PASI, phase III, psoriasis, randomized controlled trials, safety, T cells, T lymphocytes
View Abstract
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A, Gordon K, Carey W, et al.
Arch Dermatol. 2005;141:31-38.
Date Published: January 2005
Keywords: administration, adverse effects, antigens, CD11a, dermatology, Dermatology Life Quality Index (DLQI), dosage, efalizumab, efficacy, immunology, monoclonal antibodies, open-label, PASI, pathology, patient-reported outcomes, phase III, Physician's Global Assessment (PGA), pruritus, psoriasis, Psoriasis Symptom Assessment (PSA), psychology, quality of life, randomized controlled trials, safety
View Synopsis View Abstract
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB, Gordon KB, Lebwohl MG, et al, for the Efalizumab Study Group.
J Drugs Dermatol. 2004;3:614-624.
Date Published: November 2004
Keywords: administration, adverse effects, antigens, CD11a, dosage, efalizumab, efficacy, long-term treatment, monoclonal antibodies, PASI, phase III, Physician's Global Assessment (PGA), psoriasis, randomized controlled trials, safety, subcutaneous injections, toxicity
View Abstract
Efalizumab in the treatment of psoriasis.
Leonardi CL.
Dermatol Ther. 2004;17:393-400.
Date Published: October 2004
Keywords: administration, antigens, CD11a, discontinuation, dosage, efalizumab, efficacy, inflammation, LFA-1, monoclonal antibodies, PASI, pathology, phase III, psoriasis, rebound, safety, subcutaneous injections, T cells, T lymphocytes, transitioning
View Abstract
Etanercept
Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection.
Alcaide AJ, Barrera MV, Habicheyn S., et al.
J Eur Acad Dermatol Venereol. 2008;[Epub ahead of print]
Date Published: March 2008
Keywords:
View Abstract
Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series.
Esposito M, Mazzotta A, Casciello C., et al.
Dermatology. 2008;216:355-60
Date Published: February 2008
Keywords:
View Abstract
Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS, Siegfried EC, Langley RG., et al.
N Engl J Med. 2008;358:24
Date Published: January 2008
Keywords:
View Abstract
Efficacy of etanercept in psoriatic patients previously treated with infliximab.
Pitarch G, Sánchez-Carazo JL, Mahiques L., et al.
Dermatology. 2008;216:312-16
Date Published: January 2008
Keywords:
View Abstract
Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.
Krishnan R, Cella D, Leonardi C., et al.
Br J Dermatol. 2007;157:1275-7
Date Published: December 2007
Keywords:
View Abstract
The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis.
Ly L, Czarnecki D.
Br J Dermatol. 2007;157:1076-8
Date Published: November 2007
Keywords:
View Abstract
TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature.
Nair B, Raval G, Mehta P.
Am J Hematol. 2007;82:1022-4
Date Published: November 2007
Keywords:
View Abstract
CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
Campanati A, Goteri G, Simonetti O., et al.
Br J Dermatol. 2007
Date Published: October 2007
Keywords:
View Abstract
Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.
Krishnan R, Cella D, Leonardi C., et al.
Br J Dermatol. 2007
Date Published: October 2007
Keywords:
View Abstract
Cost-effectiveness of psoriasis therapy with etanercept in Germany.
Heinen-Kammerer T, Daniel D, Stratmann L., et al.
J Dtsch Dermatol Ges. 2007;5:762-8
Date Published: September 2007
Keywords:
View Abstract
Adalimumab vs. etanercept in psoriasis.
Downs AM.
Clin Exp Dermatol. 2007;32:593
Date Published: September 2007
Keywords:
View Abstract
Development of Crohn disease in a patient on etanercept for psoriasis.
Ahmad K, Rogers S.
Br J Dermatol. 2007
Date Published: June 2007
Keywords:
View Abstract
Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.
Linardaki G, Katsarou O, Ioannidou P., et al.
J Rheumatol. 2007;34:1353-5
Date Published: June 2007
Keywords:
View Abstract
Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis.
Tyring S, Gordon KB, Poulin Y., et al.
Arch Dermatol. 2007;143:719-26
Date Published: June 2007
Keywords:
View Abstract
Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 month-old child successfully treated with etanercept.
Fabrizi G, Guerriero C, Pagliarello C.
Eur J Dermatol. 2007;17:245
Date Published: May 2007
Keywords:
View Abstract
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Moore A, Gordon KB, Kang S., et al.
J Am Acad Dermatol. 2007;56:598-603
Date Published: April 2007
Keywords:
View Abstract
Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial.
Kimball AB, Jackson JM, Sobell JM., et al.
J Drugs Dermatol. 2007;6:299-306
Date Published: March 2007
Keywords:
View Abstract
Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus
Boehncke W-H, Brasie RA, Barker J., et al.
J Eur Acad Dermatol Venereol. 2006;20:988-998
Date Published: September 2006
Keywords:
View Abstract
Use of etanercept in the dermatology setting: a review [review].
Lebwohl MG.
Am J Clin Dermatol. 2005;6:49-59.
Date Published: January 2005
Keywords: administration, ankylosing spondylitis, anti-inflammatory agents, biologic agents, dermatology, efficacy, etanercept, immunoglobulin G, inflammatory, juvenile rheumatoid arthritis, National Psoriasis Foundation (NPF), phototherapy, psoriasis, psoriatic arthritis, receptors, rheumatoid arthritis, safety, survey, systemic therapy, tumor necrosis factor (TNF)
View Abstract
A randomized trial of etanercept as monotherapy for psoriasis.
Gottlieb AB, Matheson RT, Lowe N, et al.
Arch Dermatol. 2003;139:1627-1632.
Date Published: December 2003
Keywords: efficacy, etanercept, immunoglobulin G, immunosuppressive agents, monotherapy, PASI, Physician's Global Assessment (PGA), psoriasis, randomized controlled trials, receptors, retrospective studies, safety, tumor necrosis factor (TNF)
View Abstract
Immunology of Psoriasis
Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis.
Guttman-Yassky E, Lowes MA, Fuentes-Duculan J., et al.
J Immunol. 2008;181:7420-7
Date Published: November 2008
Keywords:
View Abstract
Functional Characterization of IL-17F as a Selective Neutrophil Attractant in Psoriasis.
Watanabe H, Kawaguchi M, Fujishima S., et al.
J Invest Dermatol. 2008;[Epub ahead of print]
Date Published: October 2008
Keywords:
View Abstract
Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis.
Kryczek I, Bruce AT, Gudjonsson JE., et al.
J Immunol. 2008;181:4733-41
Date Published: October 2008
Keywords:
View Abstract
A role for T cell-derived interleukin 22 in psoriatic skin inflammation.
Boniface K, Guignouard E, Pedretti N., et al.
Clin Exp Immunol. 2007;150:407-15
Date Published: December 2007
Keywords:
View Abstract
Immunopathogenesis of psoriasis.
Sabat R, Philipp S, Höflich C., et al.
Exp Dermatol. 2007;16:779-98
Date Published: October 2007
Keywords:
View Abstract
Interleukin-17 in inflammatory skin disorders.
van Beelen AJ, Teunissen MB, Kapsenberg ML., et al.
Curr Opin Allergy Clin Immunol. 2007;7:374-81
Date Published: October 2007
Keywords:
View Abstract
The immunologic basis for the treatment of psoriasis with new biologic agents.
Krueger JG.
J Am Acad Dermatol. 2002;46:1-23.
Date Published: January 2002
Keywords: biologic agents, cytokines, immunology, immunotherapy, psoriasis, T cells, T lymphocytes
View Abstract
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
Ellis CN, Krueger GG, for the Alefacept Clinical Study Group.
N Engl J Med. 2001;345:248-255.
Date Published: July 2001
Keywords: adjuvants, adverse effects, alefacept, efficacy, PASI, pathogenesis, psoriasis, recombinant fusion proteins, T cells, T lymphocytes
View Abstract
T-cell function and migration: two sides of the same coin.
von Andrian UH, Mackay CR.
N Engl J Med. 2000;343:1020-1034.
Date Published: October 2000
Keywords: B lymphocytes, cell adhesion molecules, chemokines, dendritic cells, lymphoid tissue, receptors, T cells, T lymphocytes
View Abstract
Role of T cell activation in the pathogenesis of psoriasis.
Gottlieb AB, Krueger JG, Khandke L, et al.
Ann N Y Acad Sci. 1991;636:377-379.
Date Published: December 1991
Keywords: cyclosporine, immunology, pathogenesis, psoriasis, T cells, T lymphocytes
View Abstract
Immunologic mechanisms in psoriasis [review].
Gottlieb AB.
J Am Acad Dermatol. 1988;18:1376-1380.
Date Published: November 1988
Keywords: acanthosis, cytokines, hyperplasia, immunology, inflammation, interleukins, keratinocytes, leukocytes, metabolism, psoriasis, T cells, T lymphocytes
View Abstract
Infliximab
Infliximab for the treatment of severe pustular psoriasis: 6 years later.
Varma R, Cantrell W, Elmets C., et al.
J Eur Acad Dermatol Venereol. 2008;[Epub ahead of print]
Date Published: March 2008
Keywords:
View Abstract
Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases.
Mössner R , Thaci D, Mohr J., et al.
Arch Dermatol Res. 2008;300:101-5
Date Published: March 2008
Keywords:
View Abstract
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.
Rich P, Griffiths CE, Reich K., et al.
J Am Acad Dermatol. 2008;58:224-31
Date Published: February 2008
Keywords:
View Abstract
Infliximab then efalizumab, the 'hit and run' approach does not work.
Barde C, Thielen AM, Saurat JH.
Dermatology. 2008;216:171-2
Date Published: January 2008
Keywords:
View Abstract
Pustular psoriasis induced by infliximab
C Martínez-Morán, C Sanz-Muñoz, A Mª Morales-Callaghan.
J Eur Acad Dermatol Venereol. 2007;21:1424-26
Date Published: November 2007
Keywords:
View Abstract
Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
Takahashi MD, Castro LG, Romiti R., et al.
Br J Dermatol. 2007;157:828-31
Date Published: October 2007
Keywords:
View Abstract
Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab.
Vestergaard C, Deleuran M, Kragballe K.
J Eur Acad Dermatol Venereol. 2007;21:1272-4
Date Published: October 2007
Keywords:
View Abstract
Sustained Clinical Response and High Infliximab Survival in Psoriatic Arthritis Patients: A 3-year Long-Term Study.
Voulgari PV, Venetsanopoulou AI, Exarchou SA., et al.
Semins Arthritis Rheum. 2007
Date Published: September 2007
Keywords:
View Abstract
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
Reich K, Nestle FO, Wu Y., et al.
Eur J Dermatol. 2007;17:381-6
Date Published: September 2007
Keywords:
View Abstract
Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
Haitz KA, Kalb RE.
J Am Acad Dermatol. 2007;57:120-5
Date Published: July 2007
Keywords:
View Abstract
Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis.
Marzo-Ortega H, McGonagle D, Rhodes LA., et al.
Ann Rheum Dis. 2007;66:778-81
Date Published: June 2007
Keywords:
View Abstract
Treatment of pustular psoriasis with infliximab.
Weishaupt C, Metze D, Luger TA., et al.
J Dtsch Dermatol Ges. 2007;5:397-9
Date Published: May 2007
Keywords:
View Abstract
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A, Feldman SR, Weinstein GD., et al.
J Am Acad Dermatol. 2007;56:31.e1-15
Date Published: January 2007
Keywords:
View Abstract
Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
Nestorov I, Zitnik R, DeVries T., et al.
Br J Clin Pharmacol. 2006;62:435-45
Date Published: October 2006
Keywords:
View Abstract
Remission and time of resolution of nail psoriasis during infliximab therapy.
Bianchi L, Bergamin A, de Felice C, et al.
J Am Acad Dermatol. 2005;52:736-737.
Date Published: April 2005
Keywords: infliximab, nail psoriasis, psoriasis, remission
View Abstract
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE, Kavanaugh A, Kirkham B, et al.
Arthritis Rheum. 2005;52:1227-1236.
Date Published: April 2005
Keywords: ACR, antirheumatic agents, dactylitis, dermatologic agents, efficacy, enthesitis, infliximab, intravenous, monoclonal antibodies, PASI, psoriasis, psoriatic arthritis
View Abstract
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Gottlieb AB, Evans R, Li S, et al.
J Am Acad Dermatol. 2004;51:534-542.
Date Published: October 2004
Keywords: adverse effects, efficacy, immunology, infliximab, intravenous, monoclonal antibodies, PASI, pathogenesis, Physician's Global Assessment (PGA), psoriasis, quality of life, randomized controlled trials, safety
View Abstract
Infliximab for psoriasis.
Gottlieb AB.
J Am Acad Dermatol. 2003;49(suppl 2):S112-S117.
Date Published: August 2003
Keywords: adverse effects, drug interactions, immunology, infliximab, monoclonal antibodies, psoriasis, tumor necrosis factor (TNF)
View Abstract
Psoriasis and Quality of Life
Suffering in psoriasis patients: its relation with illness severity and subjective well-being.
Reimus JL, Vingerhoets AJ, Soons PH., et al.
Int J Dermatol. 2007;46:1042-5
Date Published: October 2007
Keywords:
View Abstract
Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients.
Nijsten T, Meads DM, de Korte J., et al.
J Invest Dermatol. 2007;127:2315-22
Date Published: October 2007
Keywords:
View Abstract
Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE Study.
Finzi A, Colombo D, Caputo A., et al.
J Eur Acad Dermatol Venereol. 2007;21:1161-9
Date Published: October 2007
Keywords:
View Abstract
The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study.
Sampogna F, Tabolli S, Abeni D., et al.
Br J Dermatol. 2007;157:508-13
Date Published: September 2007
Keywords:
View Abstract
The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
Katugampola RP, Lewis VJ, Finlay AY.
Br J Dermatol.
Date Published: March 2007
Keywords:
View Abstract
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis.
Kavanaugh A, Antoni C, Mease P., et al.
J Rheumatol. 2006;33:2254-9
Date Published: November 2006
Keywords:
View Abstract
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR, Gordon KB, Bala M, et al.
Br J Dermatol. 2005;152:954-960.
Date Published: May 2005
Keywords: Dermatology Life Quality Index (DLQI), infliximab, intravenous, monoclonal antibodies, PASI, psoriasis, quality of life, tumor necrosis factor (TNF)
View Abstract
Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.
Feldman SR, Menter A, Koo JY.
Br J Dermatol. 2004;150:317-326.
Date Published: April 2004
Keywords: alefacept, Dermatology Life Quality Index (DLQI), DQOLS, psoriasis, quality of life, SF-36
View Abstract
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.
Krueger G, Koo J, Lebwohl M, et al.
Arch Dermatol. 2001;137:280-284.
Date Published: March 2001
Keywords: interpersonal, National Psoriasis Foundation (NPF), patient satisfaction, psoriasis, psychology, quality of life, questionnaire, survey
View Abstract
Psoriasis Treatment
Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
DE Oliveira JP, Levy A, Morel P., et al.
J Dermatol. 2008;35:575-80
Date Published: September 2008
Keywords:
View Abstract
Consecutive use of different biological therapies in the treatment of psoriasis.
Costanzo A, Papoutsaki M, Mazzotta A., et al.
Br J Dermatol. 2007;157:394
Date Published: August 2007
Keywords:
View Abstract
Psoriasis treatment: current and emerging directed therapies.
Winterfield LS, Menter A, Gordon K, et al.
Ann Rheum Dis. 2005;64(suppl 2):ii87-ii90.
Date Published: March 2005
Keywords: adalimumab, adverse effects, alefacept, biologic agents, cyclosporine, dermatologic agents, efalizumab, efficacy, etanercept, infliximab, methotrexate, phase II, phase III, psoriasis, psoriatic arthritis, quality of life, retinoids, systemic therapy, tumor necrosis factor (TNF)
View Abstract
Biological therapies in the systemic management of psoriasis: International Consensus Conference.
Sterry W, Barker J, Boehncke WH, et al.
Br J Dermatol. 2004;151(suppl 69):3-17.
Date Published: August 2004
Keywords: adverse effects, biologic agents, long-term treatment, pathogenesis, phototherapy, psoriasis, quality of life, safety, systemic therapy, tolerability
View Abstract
Psoriasis.
Lebwohl M.
Lancet. 2003;361:1197-1204.
Date Published: April 2003
Keywords: antirheumatic agents, dermatologic agents, immunoglobulin G, infliximab, monoclonal antibodies, psoriasis, receptors, tumor necrosis factor (TNF)
View Abstract
Biologic therapy for psoriasis: the new therapeutic frontier.
Singri P, West DP, Gordon KB.
Arch Dermatol. 2002;138:657-663.
Date Published: May 2002
Keywords: adjuvants, adverse effects, cytokines, monoclonal antibodies, psoriasis, recombinant fusion proteins, T cells, T lymphocytes
View Abstract
Treatment of psoriasis, II: systemic therapies[review].
Lebwohl M, Ali S.
J Am Acad Dermatol. 2001;45:649-661.
Date Published: November 2001
Keywords: cyclosporine, immunosuppressive agents, methotrexate, psoriasis, retinoids, systemic therapy
View Abstract
Quality of life (QOL)
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study.
Revicki DA, Menter A, Feldman S., et al.
Health Qual Life Outcomes. 2008;6:75
Date Published: October 2008
Keywords:
View Abstract
|
 |
|
REGISTER NOW
